AxoGen proposed a public offering of common stock.
The medical technology company focused on peripheral nerve repair plans to offer and sell shares of common stock in an underwritten public offering.
Here are five things to know about the offering:
1. Its still subject to market and other conditions. There is on assurance as to whether or when the offering may be complete, or the actual size or terms of the offering.
2. Wedbush PacGrow Life Sciences is acting as sole manager for the offering.
3. AxoGen plans to use net proceeds from the offering to continue sales force expansion, surgeon education programs and for general corporate purposes.
4. Offering shares is pursuant to a shelf registration statement on Form S-3, which was previously filed with the Securities and Exchange Commission and declared effective on May 9, 2014.
5. There is a preliminary prospectus supplement and accompanying prospectus related to the offering that will be filed and made available on the SEC's website.